VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 127 filers reported holding VAXCYTE INC in Q3 2022. The put-call ratio across all filers is 0.98 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $609,000 | +103.0% | 11,946 | +98.4% | 0.00% | – |
| Q2 2023 | $300,000 | +88.7% | 6,020 | +41.9% | 0.00% | – |
| Q1 2023 | $159,000 | -67.8% | 4,241 | -58.8% | 0.00% | – |
| Q4 2022 | $494,000 | +2252.4% | 10,296 | +1101.4% | 0.00% | – |
| Q3 2022 | $21,000 | +110.0% | 857 | +72.1% | 0.00% | – |
| Q2 2022 | $10,000 | -85.3% | 498 | -82.3% | 0.00% | – |
| Q1 2022 | $68,000 | -67.1% | 2,819 | -67.5% | 0.00% | – |
| Q4 2021 | $207,000 | +66.9% | 8,677 | +77.6% | 0.00% | – |
| Q3 2021 | $124,000 | +87.9% | 4,887 | +67.2% | 0.00% | – |
| Q2 2021 | $66,000 | +32.0% | 2,922 | +16.7% | 0.00% | – |
| Q1 2021 | $50,000 | +257.1% | 2,504 | +377.0% | 0.00% | – |
| Q4 2020 | $14,000 | +27.3% | 525 | +138.6% | 0.00% | – |
| Q3 2020 | $11,000 | +83.3% | 220 | +10.0% | 0.00% | – |
| Q2 2020 | $6,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |